Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

911 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.
Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F, Lode L, Richebourg S, Blanchet O, Vey N, Ifrah N, Milpied N, Blaise D, Harousseau JL, Mohty M. Chevallier P, et al. Leukemia. 2010 Feb;24(2):467-9. doi: 10.1038/leu.2009.214. Epub 2009 Oct 22. Leukemia. 2010. PMID: 19847200 No abstract available.
A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study.
Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, Filanovsky K, Cornillet-Lefebvre P, Luquet I, Lode L, Richebourg S, Blanchet O, Gachard N, Vey N, Ifrah N, Milpied N, Harousseau JL, Bene MC, Mohty M, Delaunay J. Chevallier P, et al. Leukemia. 2011 Jun;25(6):939-44. doi: 10.1038/leu.2011.25. Epub 2011 Feb 18. Leukemia. 2011. PMID: 21331073
Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Milpied N, Coste-Burel M, Imbert-Marcille BM, Mohty M. Peric Z, et al. Among authors: chevallier p. Leukemia. 2011 Jun;25(6):932-8. doi: 10.1038/leu.2011.26. Epub 2011 Feb 25. Leukemia. 2011. PMID: 21350556 Clinical Trial.
Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial.
Chevallier P, Fornecker L, Lioure B, Béné MC, Pigneux A, Recher C, Witz B, Fegueux N, Bulabois CE, Daliphard S, Bouscary D, Vey N, Delain M, Bay JO, Turlure P, Bernard M, Himberlin C, Luquet I, Ifrah N, Harousseau JL; GOELAMS. Chevallier P, et al. Leukemia. 2010 Jul;24(7):1380-5. doi: 10.1038/leu.2010.111. Epub 2010 May 27. Leukemia. 2010. PMID: 20508614 Clinical Trial. No abstract available.
Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors.
Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Moreau P, Harousseau JL, Mohty M. Brissot E, et al. Among authors: chevallier p. Bone Marrow Transplant. 2010 Apr;45(4):786-8. doi: 10.1038/bmt.2009.218. Epub 2009 Aug 31. Bone Marrow Transplant. 2010. PMID: 19718059 No abstract available.
Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors.
Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Flandrois G, Devys A, Stocco V, Cesbron A, Dehaut F, Moreau P, Harousseau JL, Mohty M. Brissot E, et al. Among authors: chevallier p. Bone Marrow Transplant. 2009 Nov;44(9):613-5. doi: 10.1038/bmt.2009.60. Epub 2009 Mar 23. Bone Marrow Transplant. 2009. PMID: 19308036 No abstract available.
911 results